INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
A study patients with recurrent glioblastoma using study drug ABT-414
Sponsor: AbbVie
Enrolling: Male and Female Patients
IRB Number: AAAQ7410
U.S. Govt. ID: NCT02343406
Contact: Ryan Shelton: 212-304-5485 /
Additional Study Information: The purpose of this study is to test whether the new drug, ABT-414, given either alone or with a drug called temozolomide, which is commonly used to treat brain tumors like yours, gives a better outcome than the standard therapy and is safe. The standard therapy can be one of two different regimens, either a drug called lomustine or temozolomide.
This study is closed
Yazmin Odia, MD
Do You Qualify?
Have you been diagnosed with glioblastoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Ryan Shelton